GRID Therapy for Extremity Soft Tissue Sarcoma
This study is investigating a radiation treatment called GRID therapy for people with extremity soft tissue sarcoma (a type of cancer in the soft tissues of your arms or legs). GRID therapy delivers a high dose of radiation to small areas of the tumor, while other areas receive a lower dose. Doctors hope this approach will improve how well the tumor responds to treatment without increasing problems with wound healing after surgery. This study will enroll 20 participants aged 18 and older. The main goal is to see if GRID therapy leads to serious wound complications within three months after surgery. The study is currently unclear on its recruitment status.
- Study design
- This is an interventional study planning to enroll 20 participants. The phase of the study is not specified.
- What's involved
- You would need to provide written informed consent and be willing and able to follow study procedures. The specific number of visits or procedures is not detailed.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for at least three months after surgery to check for wound complications.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
GRID Therapy for Extremity Soft Tissue Sarcoma
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Theodore K Yanagihara, MD. PhD · PRINCIPAL_INVESTIGATOR · UNC Lineberger Comprehensive Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Grade 2 or higher post-operative wound complications after GRID-3 months3 months
Safety will be quantified as the incidence of Grade 2 or higher post-operative wound complications after GRID, the standard of care XRT, and surgery. Wound complications will be graded according to The NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. CTCAE is a descriptive terminology that can be utilized for Adverse Event (AE) reporting. A grading (severity) scale is provided for each AE term. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.